Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 87.37M | $ 380.79M | $ 22.23M | $ 0.00 |
| Gross Profit | $ -525.00K | $ 45.22M | $ 355.35M | $ 19.24M | $ 0.00 |
| Operating Income | $ -153.29M | $ -314.73M | $ 38.80M | $ -201.34M | $ -82.69M |
| EBITDA | $ -144.16M | $ -290.98M | $ 39.89M | $ -200.85M | $ -82.64M |
| Net Income | $ -144.74M | $ -301.74M | $ 49.27M | $ -198.38M | $ -87.93M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 316.98M | $ 176.50M | $ 371.36M | $ 346.94M | $ 96.12M |
| Total Assets | $ 332.64M | $ 193.63M | $ 517.45M | $ 391.45M | $ 105.61M |
| Total Debt | $ 5.96M | $ 1.98M | $ 4.24M | $ 6.28M | $ 0.00 |
| Net Debt | $ -220.69M | $ -75.41M | $ -165.96M | $ -56.25M | $ -50.19M |
| Total Liabilities | $ 27.39M | $ 28.87M | $ 84.02M | $ 50.85M | $ 256.78M |
| Stockholders' Equity | $ 305.26M | $ 164.76M | $ 433.43M | $ 340.61M | $ -151.17M |
| Cash Flow | |||||
| Free Cash Flow | $ -123.48M | $ -167.80M | $ 10.68M | $ -182.40M | $ -75.15M |
| Operating Cash Flow | $ -123.34M | $ -167.65M | $ 11.92M | $ -179.87M | $ -74.80M |
| Investing Cash Flow | $ 14.04M | $ 75.65M | $ 92.05M | $ -238.99M | $ -46.41M |
| Financing Cash Flow | $ 257.03M | $ 348.00K | $ 3.54M | $ 431.79M | $ 158.51M |